Shimadzu (7701) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Operating income increased at a rate exceeding revenue growth, indicating a gradual improvement in profitability. Revenue was ¥3,987.2B (+3.8% YoY), operating income was ¥502.4B (+6.8%), ordinary income was ¥529.8B (+7.8%), and net income was ¥390.9B (+8.1% YoY, attributable to owners of the parent). The operating margin improved by approximately 35bp from the same period last year to 12.6%, supported by improved absorption of selling, general and administrative expenses and costs accompanying revenue growth. Progress toward the full-year forecast was 71.8% for revenue and 69.8% for operating income, both below the standard 75%, making improved profitability in Q4 the key focus for achieving the plan.

Factors Affecting Earnings

【Revenue】Revenue was ¥3,987.2B (+3.8% YoY). By segment, Measurement Instruments reached ¥918B, renewing its record high for Q3 for the ninth consecutive period. Industrial Machinery posted significant growth, with TMP recurring revenue increasing +31%, while Aircraft Equipment also recorded strong growth of +21% against a backdrop of defense demand. Medical Systems revenue increased +14%, driven by yen depreciation and demand outside Europe.

【Income and Loss】Operating income was ¥502.4B (+6.8% YoY), and ordinary income was ¥529.8B (+7.8%), achieving profit growth exceeding revenue growth. The approximately ¥27.5B gap between ordinary income and operating income was primarily attributable to foreign exchange gains of ¥19.2B. Extraordinary income and losses consisted of income of ¥1.9B and losses of ¥2.3B, respectively, and were minor on a net basis. Net income of ¥390.9B was primarily supported by recurring earnings power. In conclusion, the Company achieved revenue and profit growth.

Segment Analysis

The core business with the largest composition ratio is Analytical and Measuring Instruments, which generated revenue of ¥2,599.6B (65.2% of total) and operating income of ¥355.7B (13.7% margin), driving more than half of total Company profit. Industrial Machinery recorded operating income of ¥81.2B (15.7% margin), posting substantial profit growth due to recovery in TMP market conditions. Aircraft Equipment recorded operating income of ¥59.7B (19.7% margin), the highest margin among all segments, supported by defense-related demand. Medical Systems generated operating income of ¥24.6B (4.7% margin), representing relatively low profitability. Although it posted substantial profit growth year on year, there remains a significant gap in margins among the segments. Overall profit growth was supported by the scale of Analytical and Measuring Instruments and the strong growth of Industrial Machinery and Aircraft Equipment.

Key Financial Indicators

Profitability: ROE of 7.4% and operating margin of 12.6% (approximately 35bp improvement year on year). Financial soundness: An equity ratio of 77.0% and a current ratio of 345.1% indicate an extremely conservative financial structure. Per-share indicators: EPS of ¥135.28 (¥122.94 in the same period last year, +10.0%). Working capital efficiency: Trade receivables of ¥1,445.1B and inventories of ¥889.0B account for a combined approximately 33.8% of total assets, indicating room for improvement in asset turnover.

Cash Flow Analysis

Actual figures for operating cash flow (OCF), investing cash flow, and financing cash flow were not included in the disclosed data, making it difficult to assess the absolute level of cash flows. Cash and deposits stood at ¥1,456.8B, a substantial level exceeding current liabilities of ¥1,352.8B. The increase in inventories (finished products of ¥889.0B, work in process of ¥344.1B, and raw materials of ¥355.5B) appears to reflect inventory buildup accompanying the recovery in demand for semiconductor manufacturing equipment, representing a factor tying up working capital. Contract liabilities of ¥439.4B indicate advance receipts from customers and partially mitigate the working capital burden.

Quality of Earnings

The difference between ordinary income of ¥529.8B and net income of ¥390.9B was primarily attributable to income taxes and other taxes of ¥138.6B, within the range of recurring tax burdens. Non-operating income of ¥44.2B represented only 1.1% of revenue, but the ¥19.2B in foreign exchange gains included therein is subject to market conditions. Accordingly, the increase in ordinary income should not be equated entirely with improvement in operating activities. Extraordinary income and losses were minor on a net basis (income of ¥1.9B and losses of ¥2.3B) and did not materially distort earnings quality. If the pace of increase in trade receivables and inventories exceeds operating income growth, attention will be required regarding the quality of future cash flows.

Earnings Forecast and Guidance

The full-year forecast is revenue of ¥5,550B (+3.0% YoY), operating income of ¥720B (+0.4%), and ordinary income of ¥720B (0.0%). While revenue was revised upward to reflect yen depreciation, operating income was left unchanged due to anticipated increases in M&A expenses and research and development expenses. The progress rates for the nine months ended Q3 were 71.8% for revenue, 69.8% for operating income, and 73.6% for ordinary income, all below the standard 75% progress level. Operating income for Measurement Instruments was revised downward due to increased M&A expenses, while the Medical, Industrial, and Aircraft segments were revised upward on strong demand and foreign exchange effects, providing overall support.

Shareholder Returns

The Q2 dividend was ¥27 per share, and the full-year dividend forecast is ¥67, representing an expected increase from ¥26 in the previous fiscal year. Based on projected full-year EPS of ¥186.89, the forecast payout ratio is approximately 35.8%. Given the robust financial foundation of cash and deposits of ¥1,456.8B and an equity ratio of 77.0%, there is little concern regarding dividend sustainability. No disclosure regarding share buybacks was available, and this report therefore presents only the payout ratio.

Catalysts

【Short Term】Q4 earnings progress (an increase in the operating margin is required to achieve the full-year plan), realization of synergies from the acquisition of Tescan, and the launch of new products in the semiconductor, materials, and life sciences fields.

【Long Term】Announcement of the new medium-term management plan (FY2026–FY2028) scheduled for June 2026, and the sustainability of TMP demand for semiconductor manufacturing equipment and defense-related demand for Aircraft Equipment.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the operating margin and net profit margin exceed the industry median, placing the Company in the upper tier of the industry.

Growth and Capital Efficiency

The revenue growth rate is slightly above the industry median but remains at a standard level, falling short of the IQR upper bound of 8.9%.

Source: Compiled by the Company

Risk Factors

1. Prolonged working capital cycle: Trade receivables of ¥1,445.1B and inventories of ¥889.0B account for approximately 33.8% of total assets, and improvements in collection and inventory efficiency may affect future cash generation capacity.

2. Foreign exchange and tariff fluctuations: Foreign exchange gains of ¥19.2B are equivalent to 3.8% of operating income, and appreciation of the yen would be a factor weighing on ordinary income. Tariff impacts are acting as downward pressure on operating income, both directly and indirectly.

3. Segment-specific demand fluctuations: Regional and product-specific demand fluctuations, including declining pharmaceutical-related capital investment in North America for Measurement Instruments and delays in the execution of government budgets in Europe for Medical Systems, are affecting the earnings of certain segments.

Key Takeaways from the Earnings Report

1. The operating margin improved from the same period last year to 12.6%, exceeding the industry median of 8.6% by 4.0pt. While Analytical and Measuring Instruments remains the core business, growth in the high-margin Industrial Machinery and Aircraft Equipment segments is supporting the earnings structure.

2. Progress toward the full-year plan is 69.8% for operating income, below the standard progress level of 75%, making improved profitability in Q4 the decisive factor in achieving the plan.

3. The full-year dividend is expected to increase to ¥67, with the forecast payout ratio remaining at approximately 35.8%. The conservative financial foundation, including an equity ratio of 77.0%, provides structural support for the stability of the dividend policy.

Theoretical Share Price (For Reference)

Sensitivity: ¥1,846–¥1,954 at ±1% for the cost of equity, and ¥1,898–¥1,901 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical values may be calculated somewhat higher.

(Calculation model: Residual income model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated values based solely on publicly disclosed data; these are not forecasts of market share prices or recommendations of specific investment actions, and do not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated through an AI-integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Shimadzu delivered a solid FY2026 Q3 result, with profit growth exceeding sales growth and a modest expansion in operating profitability. Revenue rose 3.8% year on year to ¥398.7bn. Operating income increased 6.8% to ¥50.2bn. Ordinary income rose 7.8% to ¥53.0bn. Net income attributable to owners increased 8.1% to ¥39.1bn. The operating margin improved by 36 basis points to 12.6%, from 12.2% a year earlier. Gross margin expanded by approximately 167 basis points to 45.0%, indicating that gross-profit growth outpaced revenue growth. This gross-margin improvement more than offset an approximately 8.0% increase in SG&A expense, which grew faster than revenue. Net profit margin was 9.8%, placing profitability in the upper end of the generally healthy 5-10% range. Ordinary income exceeded operating income by ¥2.7bn, supported partly by non-operating income of ¥4.4bn. Foreign-exchange gains of ¥1.9bn were a meaningful, though not dominant, contributor to non-operating income. Interest income of ¥1.1bn substantially exceeded interest expense of ¥0.2bn, consistent with a net-cash balance sheet. Extraordinary items were immaterial: the ¥0.2bn gain on asset sales was broadly offset by a ¥0.2bn loss on disposal of fixed assets. Comprehensive income increased more rapidly than net income, reaching ¥52.9bn, helped by positive foreign-currency translation effects. The balance sheet remains highly liquid, with cash and deposits of ¥145.7bn, a current ratio of 345.1%, and only ¥0.9bn of reported interest-bearing debt. Working-capital intensity remains the principal operating issue, with receivable and inventory diagnostics indicating a long cash-conversion cycle. Against full-year guidance, Q3 cumulative revenue, operating income and net income progress are slightly below the conventional 75% seasonal benchmark, implying a stronger final quarter is required. The implied Q4 operating margin required to achieve the full-year operating-income forecast is approximately 13.9%, above the 12.6% achieved in the first nine months. Full-year dividend guidance of ¥67 per share implies a reasonable dividend payout ratio of approximately 35.8% against forecast EPS of ¥186.89. Overall, the quarter supports an earnings profile of resilient core profitability and exceptional financial flexibility, while placing execution emphasis on Q4 margin delivery and working-capital discipline.

Profitability Analysis

The reported annualized DuPont ROE is 9.8%, composed of a 9.8% net profit margin, 0.770x asset turnover, and 1.30x financial leverage. The principal contributor to return is profitability rather than leverage, as the 1.30x leverage factor reflects a conservatively financed balance sheet. Net margin remained just below the 10% threshold generally associated with excellent profitability, but operating-margin expansion and faster profit growth than revenue indicate improving earnings conversion. Operating income increased by ¥3.2bn year on year, versus a ¥14.4bn increase in revenue. Gross profit rose 7.7% to ¥179.3bn, while gross margin improved to 45.0% from approximately 43.3%. SG&A expenses increased to ¥129.1bn from ¥119.5bn, or about 8.0% year on year, exceeding the 3.8% revenue-growth rate. This means the gross-margin gain, rather than SG&A leverage, was the source of operating-margin expansion. The annualized asset-turnover factor of 0.770x is moderate for a precision-instrument manufacturer and reflects a sizable cash, receivable and inventory base. Financial leverage is low and sustainable, supported by equity of ¥531.4bn against total assets of ¥690.6bn. The five-factor framework also indicates low financing strain: the interest burden is 1.054, because non-operating income exceeds interest expense, while interest coverage is an exceptionally strong 229.39x. The 0.738 tax burden corresponds to a 26.2% effective tax rate and appears normal. Non-operating income represented only 1.1% of revenue, below the 5% threshold that would materially dilute the operating earnings signal. The approximately ¥1.9bn FX gain equaled 3.8% of operating income, so currency movements enhanced but did not define earnings. Under JGAAP, goodwill amortization can depress operating profit, but the reported goodwill balance is only ¥7.5bn, or 1.4% of equity, limiting balance-sheet M&A distortion.

Growth Assessment

Revenue growth of 3.8% was moderate, but operating-income growth of 6.8% and net-income growth of 8.1% demonstrate favorable profit conversion. Gross-margin expansion provides evidence that growth was accompanied by improved pricing, mix, manufacturing efficiency, or some combination of these factors. However, SG&A growth exceeded revenue growth, making cost containment important for sustaining further margin gains. The company has guided to FY2026 revenue of ¥555.0bn, operating income of ¥72.0bn and net income of ¥54.0bn. Q3 cumulative revenue represents 71.8% of full-year guidance, 3.2 percentage points below the standard 75% Q3 progress rate. Operating income progress is 69.8%, or 5.2 percentage points below the standard rate. Net income progress is 72.4%, or 2.6 percentage points below the standard rate. None of these deviations exceeds the 10-percentage-point threshold that would independently signal a severe guidance-execution gap. Achieving the forecast requires Q4 revenue of ¥156.3bn, operating income of ¥21.8bn and net income of ¥14.9bn. The implied Q4 operating margin of approximately 13.9% is 128 basis points above the nine-month margin, making year-end product mix, production utilization and SG&A absorption important. The full-year forecast implies 3.0% revenue growth and only 0.4% operating-income growth, indicating that management guidance embeds a material deceleration in year-on-year operating-profit growth during Q4. Inventory composition shows ¥35.6bn of raw materials, ¥34.4bn of work in process and ¥88.9bn of finished goods, with finished goods the largest identified category. This inventory profile heightens sensitivity to demand timing, production planning and potential product obsolescence in analytical and measurement equipment markets.

Financial Health

Financial health is exceptionally strong. Current assets of ¥466.8bn exceed current liabilities of ¥135.3bn by ¥331.6bn, producing a current ratio of 345.1%. The quick ratio is also very high at 279.4%, indicating that liquidity does not depend on inventory liquidation. Cash and deposits of ¥145.7bn exceed reported short-term loans of ¥0.9bn by 168.03x. Debt to equity is only 0.30x on the reported ratio basis, while debt to capital is 0.2%, both well below conservative solvency thresholds. Interest coverage of 229.39x confirms that financing costs are immaterial relative to operating earnings. All reported debt is short-term, producing the refinancing-risk alert because the short-term debt ratio is 100%, above the 40% alert threshold. The root cause is the absence of reported long-term borrowings rather than a high absolute debt burden. In context, this is not a material maturity-mismatch concern because short-term loans of ¥0.9bn equal only 0.6% of cash and deposits and are amply covered by current assets. The investment impact is limited: refinancing would not be expected to constrain operations under the present capital structure. Current liabilities declined 10.6% year on year, while current assets increased 2.7%, further strengthening near-term liquidity. Contract liabilities were ¥43.9bn, providing a meaningful source of operating funding and reflecting customer advances or contractual obligations. Lease obligations totaled ¥11.1bn across current and non-current portions, remaining modest relative to equity. Net defined-benefit liability was ¥14.6bn, also manageable relative to the capital base. Equity increased 6.7% year on year to ¥531.5bn, and the capital adequacy ratio improved to 77.0% from 74.1%.

Notable B/S Changes

Short-term loans: -¥0.5bn (-36.6%) to ¥0.9bn - reported debt remains negligible and the decline further reduces already limited refinancing exposure. Investment securities: +¥5.0bn (+33.0%) to ¥20.2bn - increases exposure to equity-market valuation movements, though the portfolio remains modest at 2.9% of total assets.

Cash Flow Quality

Dividend Sustainability

The interim dividend was ¥27 per share, compared with ¥26 per share in the prior-year comparable period. The calculated payout ratio based on the reported Q2 dividend and nine-month net income is 20.5%. Full-year dividend guidance is ¥67 per share, which implies a dividend payout ratio of approximately 35.8% against forecast EPS of ¥186.89. This is comfortably below the 60% benchmark generally associated with sustainable dividend distributions. The implied remaining year-end dividend is ¥40 per share after the ¥27 interim payment. Retained earnings of ¥431.2bn provide a substantial accounting buffer relative to the expected annual dividend commitment. The company’s low reported debt, substantial cash balance and high liquidity also support balance-sheet capacity for distributions. Treasury shares of 7.1m shares, representing approximately 2.4% of issued shares, are present, but no current-period buyback amount is provided; therefore, dividend payout rather than total return is the appropriate distribution metric. Dividend sustainability is principally dependent on maintaining the guided ¥54.0bn annual net income and preserving disciplined working-capital management.

Risk Assessment

Business risks include Working-capital intensity is the most material operating risk. The reported annualized receivable-days alert of 99 days exceeds both the 60-day warning level and the 45-day efficiency benchmark, indicating relatively slow conversion of sales into customer collections., The root cause of the high-receivable-days alert is the ¥144.5bn receivables balance relative to annualized nine-month revenue. For capital-equipment and scientific-instrument sales, extended acceptance, installation and customer payment cycles can be structurally longer than in consumables businesses; nevertheless, the balance remains important because it ties up capital and raises sensitivity to customer-payment timing., The impact of slow collections is primarily on working-capital absorption and the timing of cash realization rather than on near-term solvency, given the company’s large liquidity buffer., Inventory diagnostics are elevated. One reported annualized DIO measure is 111 days, above the 60-day manufacturing benchmark, while a separate quality alert cites 198 days, above the 90-day warning threshold., The root cause of the high-inventory alerts is a large inventory balance of ¥88.9bn, including identified raw materials of ¥35.6bn, work in process of ¥34.4bn and finished goods of ¥88.9bn. The differing diagnostic measures both point to capital tied up in the production and delivery cycle., For a manufacturer of analytical, medical and industrial instruments, inventories can reflect long lead-time components, configured systems and customer delivery schedules. The impact is a higher risk of demand-forecast errors, aging finished goods, margin pressure from discounts, and delayed conversion of production into sales., The long cash-conversion-cycle alert of 248 days, above the 120-day warning level, combines slow collections and inventory intensity. This is a material efficiency issue even though it does not currently create a liquidity threat., The annualized 111-day inventory-days diagnostic and the 248-day cash-cycle alert should be monitored as complementary measures of working-capital risk rather than as evidence of balance-sheet stress, because the company retains very large liquid resources., Industry-specific risks include research and laboratory-equipment demand cyclicality, public and private research-budget timing, healthcare capital-spending trends, procurement lead times for specialized components, and foreign-exchange exposure on international sales and sourcing., FX gains of ¥1.9bn contributed to ordinary income; a reversal in exchange rates could reduce non-operating earnings, although the current contribution is not large relative to operating profit..

Financial risks include The refinancing-risk alert is mechanically triggered because 100% of reported interest-bearing debt is short-term. The absolute ¥0.9bn short-term-loan balance is immaterial relative to ¥145.7bn of cash, a 345.1% current ratio and 168.03x cash-to-short-term-debt coverage, substantially mitigating refinancing risk., Investment securities increased 33.0% year on year to ¥20.2bn. This increases exposure to market valuation movements, although the balance represents only 2.9% of total assets., Accumulated other comprehensive income rose alongside foreign-currency translation adjustments and securities valuation gains. These items strengthen reported equity but can reverse with exchange-rate and market-price movements., Goodwill of ¥7.5bn is only 1.4% of equity and 1.1% of assets, so M&A-related impairment risk is currently low. Intangible assets are also modest at 3.6% of total assets..

Key concerns include Q4 execution is important because full-year operating-income guidance requires an implied 13.9% Q4 operating margin, above the 12.6% margin achieved through Q3., SG&A expense growth of approximately 8.0% exceeded revenue growth of 3.8%; sustained margin expansion therefore depends on continued gross-margin improvement or improved overhead absorption., Receivable collection, inventory normalization and cash-cycle improvement are the most relevant operating metrics to monitor alongside the final-quarter margin outcome..

Investment Implications

Key takeaways include Revenue rose 3.8%, while operating income and net income increased 6.8% and 8.1%, respectively, demonstrating positive profit conversion., Operating margin improved to 12.6% and gross margin to 45.0%, although SG&A growth remained above sales growth., The balance sheet is a major strength, with ¥145.7bn of cash, a 345.1% current ratio, 77.0% capital adequacy and negligible reported interest-bearing debt., Working-capital efficiency is the principal area requiring attention, as receivable days, inventory days and the cash-conversion-cycle alerts are all elevated., Full-year guidance remains within reach, but the implied Q4 operating margin of about 13.9% requires stronger profitability than the nine-month average., The forecast ¥67 annual dividend implies an approximately 35.8% payout ratio, leaving substantial retained earnings and balance-sheet capacity..

Metrics to watch include Q4 operating margin versus the approximately 13.9% implied by full-year guidance, Revenue and operating-income progress against ¥555.0bn and ¥72.0bn full-year guidance, Annualized receivable days, currently flagged at 99 days, Inventory days, currently flagged at 111 days and separately at 198 days, Cash conversion cycle, currently flagged at 248 days, SG&A growth relative to revenue growth, Foreign-exchange gains or losses within non-operating income, Investment-securities valuation movements following the 33.0% year-on-year increase.

Regarding relative positioning, Shimadzu combines good manufacturing-sector profitability, a 12.6% operating margin, and unusually conservative balance-sheet leverage. Its principal relative limitation is not solvency but working-capital efficiency: extended collection and inventory cycles can depress capital efficiency and make earnings-to-cash conversion more sensitive to order fulfillment and customer acceptance timing.